Please join us during our Community Webinar Series on April 17th as we welcome the team from Dyne Therapeutics to speak on updates to the DELIVER trial of DYNE-251 in males with Duchenne mutations amenable to exon 51 skipping.
Clinical Impact of FORCETM Platform in Duchenne
April 17, 2025 | 1pm ET| Zoom
Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!
Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.
